IP Library Granted Patent US 9,301,977
Granted Patent B2
US 9,301,977 · App. 14/173,494 · Granted Apr 5, 2016

Method for allogeneic cell therapy

Inventor: Michael Har-Noy (Jerusalem, IL)
Assignee: IMMUNOVATIVE THERAPIES, LTD.
A61K35/17A61K39/0005C12N5/0636A61K2039/5154A61K2039/57C12N2501/51C12N2501/515C12N2531/00C12N2533/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,301,977
App. No.
14/173,494
Granted
Apr 5, 2016
Kind
B2
Abstract

A method of manipulating allogeneic cells for use in allogeneic cell therapy providing a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism, or “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect The anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used to stimulate host immunity in a complete HLA mis-matched setting in a patient.

Claims (5)

1. A method of allogeneic transplant into a host that provides an anti-tumor effect without GVHD toxicity to the host, the method comprising:

infusing into the host allogeneic cells of which at least a portion are

activated T-cells derived from a tissue mis-matched normal donor and wherein said allogeneic cells are rejected by the host.

2. The method of claim 1 wherein at least a portion of the allogeneic T-cells are Th1 cells.

3. The method of claim 1 wherein the allogeneic T-cells are activated by cross-linking CD3 and CD28 surface antigens.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE ADDRESS OS THE ASSIGNEE PREVIOUSLY RECORDED AT REEL: 050489 FRAME: 0245. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 28, 2020
From: HAR-NOY, MICHAEL
To: MIRROR BIOLOGICS, INC.
Reel/Frame 052915/0513 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME FROM IMMUNOVATIVE THERAPIES, LTD. TO MICHAEL HAR-NOY ON THE ORIGINAL COVER SHEET PREVIOUSLY RECORDED ON REEL 050489 FRAME 0245. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 2, 2019
From: HAR-NOY, MICHAEL
To: MIRROR BIOLOGICS, INC.
Reel/Frame 050610/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2019
From: IMMUNOVATIVE THERAPIES, LTD.
To: MIRROR BIOLOGICS, INC.
Reel/Frame 050489/0245 →
RESCISSION Recorded Sep 12, 2019
From: HAR-NOY, MICHAEL
To: HAR-NOY, MICHAEL
Reel/Frame 050467/0081 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2016
From: HAR-NOY, MICHAEL
To: IMMUNOVATIVE THERAPIES, LTD.
Reel/Frame 037599/0968 →
Continuity (5)
Division 13596142 · Aug 28, 2012
Division 12869490 · Aug 26, 2010
Continuation 12172594 · Jul 14, 2008
Division 10838454 · May 4, 2004
Related Publication 20140154278A1 · Jun 5, 2014